These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17984555)

  • 1. [Oral spiramycin for prevention of restenosis in coronary arteries].
    Aleksiadi ER; Shaburishvili TSh
    Georgian Med News; 2007 Sep; (150):11-3. PubMed ID: 17984555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
    Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
    J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial.
    Bestehorn HP; Neumann FJ; Büttner HJ; Betz P; Stürzenhofecker P; von Hodenberg E; Verdun A; Levai L; Monassier JP; Roskamm H
    J Am Coll Cardiol; 2004 Jun; 43(12):2160-5. PubMed ID: 15193674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
    Rodriguez A; Rodríguez Alemparte M; Fernández Pereira C; Sampaolesi A; da Rocha Loures Bueno R; Vigo F; Obregón A; Palacios IF;
    Am J Med; 2005 Jul; 118(7):743-51. PubMed ID: 15989908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
    Waksman R; Ajani AE; Pichard AD; Torguson R; Pinnow E; Canos D; Satler LF; Kent KM; Kuchulakanti P; Pappas C; Gambone L; Weissman N; Abbott MC; Lindsay J;
    J Am Coll Cardiol; 2004 Oct; 44(7):1386-92. PubMed ID: 15464317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
    Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical follow-up of sirolimus-eluting (CYPHER) coronary stents in the treatment of instent restenosis in an unselected population.
    Ruchin PE; Muller DW; Faddy SC; Baron DW; Roy PR; Wilson SH
    Heart Lung Circ; 2007 Dec; 16(6):440-6. PubMed ID: 17669686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
    Ardissino D; Cavallini C; Bramucci E; Indolfi C; Marzocchi A; Manari A; Angeloni G; Carosio G; Bonizzoni E; Colusso S; Repetto M; Merlini PA;
    JAMA; 2004 Dec; 292(22):2727-34. PubMed ID: 15585732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
    Hausleiter J; Kastrati A; Mehilli J; Vogeser M; Zohlnhöfer D; Schühlen H; Goos C; Pache J; Dotzer F; Pogatsa-Murray G; Dirschinger J; Heemann U; Schömig A;
    Circulation; 2004 Aug; 110(7):790-5. PubMed ID: 15302787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
    Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
    Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Feres F; Staico R; Centemero M; Tanajura LF; Abizaid AC; Rodrigues A; Paes A; Mintz GS; Sousa JE
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):535-40. PubMed ID: 16283682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
    Schofer J; Schlüter M; Gershlick AH; Wijns W; Garcia E; Schampaert E; Breithardt G;
    Lancet; 2003 Oct; 362(9390):1093-9. PubMed ID: 14550694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results and predictors of angiographic restenosis and long-term adverse cardiac events after drug-eluting stent implantation for aorto-ostial coronary artery disease.
    Park DW; Hong MK; Suh IW; Hwang ES; Lee SW; Jeong YH; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2007 Mar; 99(6):760-5. PubMed ID: 17350360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
    Guarda E; Marchant E; Fajuri A; Martínez A; Morán S; Mendez M; Uriarte P; Valenzuela E; Lazen R
    Am Heart J; 2004 Aug; 148(2):e9. PubMed ID: 15309012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of J&J Crown stent versus NIR stent after routine coronary angioplasty.
    Miketic S; Carlsson J; Tebbe U
    Am Heart J; 2001 Nov; 142(5):E8. PubMed ID: 11685183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.